Upon studying the compound, it was also found that this drug forms stable complexes with PD-L1 [104], thus presenting a new strategy for the treatment of cancers using liothyronine to inhibit the PD-1/PD-L1 interaction and enhance the capacity of immune cells to fight cancer. This evidence concerns the gene PDCD1 and cancer.